T-Cell Turnover Following Vaccination With MVA85A

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Tuberculosis
Interventions
BIOLOGICAL

MVA85A

Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.

OTHER

Deuterated glucose infusion

6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).

Trial Locations (1)

OX3 7LJ

University of Oxford, Oxford

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

collaborator

St George's, University of London

OTHER

lead

University of Oxford

OTHER

NCT00548444 - T-Cell Turnover Following Vaccination With MVA85A | Biotech Hunter | Biotech Hunter